WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Beijing Strong Biotechnologies, Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact
Antheia | August 13, 2021
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development and production of essential medicines. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ: SRNG), serves customers across industries seeking to develop new and better products. Antheia plans to leverage Ginkgo...
Medical
GT Biopharma | December 23, 2020
GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology organization focused in on innovative treatments dependent on the Company's restrictive NK cell engager (TriKE™) innovation stage is satisfied to report the introduction of extra interval information results for the Company's lead therapeutic competitor, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, i...
PR Newswire | June 09, 2020
The impending marriage of the biotech industry and the legal (i.e. medical) cannabis industry is looking like it will be a long and happy marriage. As the use of legal marijuana grows globally, the medicinal (as opposed to recreational) revenues will continue to grow and become the dominant share of the legal marijuana market. According to Grand View Research the global legal marijuana market size is expected to reach USD 73.6 billion by 2027. It is anticipated to expand at a CAGR of 18.1% durin...
TrialSpark | December 21, 2020
TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug developm...
Whitepaper
Cell and Gene Therapy
Video
Cell and Gene Therapy, Medical
Medical, Industry Outlook
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE